Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CPS1 | P31327 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896483 | 0.87 | L3MBTL1 (0.43) | ALDH1A1NPSR1HPGDMAPTTP53 | |
| SCHEMBL4886327 | 0.86 | POLB (0.46) | SMN1; SMN2ALDH1A1NPSR1MAPTMAPK1 | |
| SCHEMBL4895411 | 0.86 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1NPSR1TP53 | |
| SCHEMBL4893101 | 0.84 | ALDH1A1 (0.37) | ALDH1A1NPSR1MAPTTSHRL3MBTL1 | |
| SCHEMBL4896113 | 0.83 | MAPK1 (0.52) | SMN1; SMN2ALDH1A1NPSR1HPGDTSHR | |
| SCHEMBL14103281 | 0.82 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1NPSR1HPGDRAB9A | |
| SCHEMBL4908569 | 0.82 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1NPSR1HPGDL3MBTL1 | |
| SCHEMBL4908582 | 0.82 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1NPSR1HPGDL3MBTL1 | |
| SCHEMBL4893013 | 0.81 | MEN1 (0.48) | ALDH1A1MAPTRAB9A | |
| SCHEMBL4887377 | 0.79 | POLB (0.43) | SMN1; SMN2ALDH1A1NPSR1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | SMN1; SMN2 4735/4885ALDH1A1 276/4885NPSR1 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.